Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) and MaxCyte (NASDAQ:MXCT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Institutional and Insider Ownership
52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Rapid Micro Biosystems has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapid Micro Biosystems | $33.59 million | 1.66 | -$47.12 million | ($1.12) | -0.99 |
| MaxCyte | $33.03 million | 3.69 | -$44.63 million | ($0.33) | -3.58 |
MaxCyte has lower revenue, but higher earnings than Rapid Micro Biosystems. MaxCyte is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Rapid Micro Biosystems and MaxCyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapid Micro Biosystems | -145.56% | -177.04% | -73.12% |
| MaxCyte | -114.77% | -18.92% | -16.14% |
Analyst Ratings
This is a summary of recent ratings and target prices for Rapid Micro Biosystems and MaxCyte, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapid Micro Biosystems | 1 | 0 | 2 | 0 | 2.33 |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
Rapid Micro Biosystems currently has a consensus target price of $6.00, indicating a potential upside of 440.54%. MaxCyte has a consensus target price of $5.00, indicating a potential upside of 323.73%. Given Rapid Micro Biosystems’ stronger consensus rating and higher possible upside, research analysts plainly believe Rapid Micro Biosystems is more favorable than MaxCyte.
Summary
MaxCyte beats Rapid Micro Biosystems on 8 of the 14 factors compared between the two stocks.
About Rapid Micro Biosystems
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
